Long-Term Successful Treatment of Indolent Systemic Mastocytosis With Omalizumab

Samuel L Weiss; John B Hyman; Geoffrey S Carlson; Christopher A Coop

doi:10.12788/fp.0081

Long-Term Successful Treatment of Indolent Systemic Mastocytosis With Omalizumab

Samuel L Weiss, John B Hyman, Geoffrey S Carlson, Christopher A Coop

Research output: Contribution to journal › Article › peer-review

Abstract

This case study suggests that omalizumab may help prevent anaphylaxis and reduce disease burden associated with systemic mastocytosis, but further studies and formal clinical trials are needed to confirm these findings.

Original language	English
Pages (from-to)	44-48
Number of pages	5
Journal	Federal practitioner : for the health care professionals of the VA, DoD, and PHS
Volume	38
Issue number	1
DOIs	https://doi.org/10.12788/fp.0081
State	Published - Jan 2021
Externally published	Yes

Access to Document

10.12788/fp.0081

Cite this

@article{b5127491935b4e59b4a9fe1e509f494a,

title = "Long-Term Successful Treatment of Indolent Systemic Mastocytosis With Omalizumab",

abstract = "This case study suggests that omalizumab may help prevent anaphylaxis and reduce disease burden associated with systemic mastocytosis, but further studies and formal clinical trials are needed to confirm these findings.",

author = "Weiss, {Samuel L} and Hyman, {John B} and Carlson, {Geoffrey S} and Coop, {Christopher A}",

note = "Copyright {\textcopyright} 2021 Frontline Medical Communications Inc., Parsippany, NJ, USA.",

year = "2021",

month = jan,

doi = "10.12788/fp.0081",

language = "English",

volume = "38",

pages = "44--48",

journal = "Federal practitioner : for the health care professionals of the VA, DoD, and PHS",

issn = "1078-4497",

number = "1",

}

TY - JOUR

T1 - Long-Term Successful Treatment of Indolent Systemic Mastocytosis With Omalizumab

AU - Weiss, Samuel L

AU - Hyman, John B

AU - Carlson, Geoffrey S

AU - Coop, Christopher A

PY - 2021/1

Y1 - 2021/1

N2 - This case study suggests that omalizumab may help prevent anaphylaxis and reduce disease burden associated with systemic mastocytosis, but further studies and formal clinical trials are needed to confirm these findings.

AB - This case study suggests that omalizumab may help prevent anaphylaxis and reduce disease burden associated with systemic mastocytosis, but further studies and formal clinical trials are needed to confirm these findings.

U2 - 10.12788/fp.0081

DO - 10.12788/fp.0081

M3 - Article

C2 - 33574649

SN - 1078-4497

VL - 38

SP - 44

EP - 48

JO - Federal practitioner : for the health care professionals of the VA, DoD, and PHS

JF - Federal practitioner : for the health care professionals of the VA, DoD, and PHS

IS - 1

ER -

Long-Term Successful Treatment of Indolent Systemic Mastocytosis With Omalizumab

Abstract

Access to Document

Fingerprint

Cite this